Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood. 2021 Jan 7;137(1):49-60. doi: 10.1182/blood.2020006731.
Blood. 2021.
PMID: 32693406
Free article.
Clinical Trial.